A new approach to the modular, complex systems analysis of nonlinear dynamics in cell cycling network transformations involved in carcinogenesis is proposed. 
D and p27 serves also some yet unidentified function in differentiation-related processes. Thus, loss of p27 not only causes unrestricted growth due to inefficient inhibition of CDK2-cyclin E/A, but may also elicit a decrease in levels of D-type cyclins, resulting in differentiation defects. Upon ablation of cyclin D, cells lose their ability to titrate p27 from CDK2-cyclin A/E complexes and proliferation is suppressed. However, defects in differentiation caused by the absence of D-cyclin are reminiscent to defects produced by the absence of p27 (Bryja et al., 2004) . When the changes in levels of p27 and/or D-type cyclins occur, an equilibrium alteration could result between proliferation/differentiation processes that may in the end result in tumorigenesis (Bryja et al., 2004) .
D1 vs. E Cyclins
The D-type and E-type cyclins control the G1 S phase transition during normal cell cycling and are important components of steroid-and growth factor-induced mitogenesis in breast epithelial cells (Sutherland and Musgrove, 2004) . Cyclin D1 null mice are resistant to breast cancer that is induced by the neu and ras oncogenes, which suggests a pivotal role for cyclin D1 in the development of some mammary carcinomas (Sutherland and Musgrove, 2004) . Cyclin D1 and E1 are usually overexpressed in breast cancer, with some association with adverse outcomes, which is likely due in part to their ability to confer resistance to endocrine therapies. The consequences of cyclin E overexpression in breast cancer are related to cyclin E's role in cell cycle progression, and that of cyclin D1 may also be a consequence of a role in transcriptional regulation (Sutherland and Musgrove, 2004) . One critical pathway determining cell cycle transition rates of G1 S phase is the cyclin/cyclin-dependent kinase (Cdk)/ p16Ink4A/ retinoblastoma protein (pRb) pathway (Sutherland and Musgrove, 2004) . Alterations of different components of this particular pathway are very ubiquitous in human cancer (Malumbres and Barbacid, 2001 ).
There appears to be a certain degree of tissue specificity in the genetic abnormalities within the Rb pathway. A model relating Rb to cyclin control in the overall scheme of pro-apoptotic behavior is shown below in Fig.1 . In breast cancer these abnormalities include the overexpression of cyclins D1, D3 and E1, the decreased expression of the p27Kip1 CKI and p16Ink4A gene silencing through promoter methylation. These aberrations occur with high frequency in breast cancer, as each abnormality occurs in ~40% of primary tumors. This fact implicates a major role for the loss of function of the Rb pathway in breast cancer. Cyclin D1 is the product of the CCND1 gene and was first connected to breast cancer after localization of the gene to chromosome 11q13, a region commonly amplified in several human carcinomas, including ~15% of breast cancers (Ormandy et al., 2003) . The fact that cyclin D1 was overexpressed at the mRNA and protein levels in 50% of primary breast cancers have caused cyclin D1 to be considered one of the most commonly overexpressed breast cancer oncogenes (Gillett et al., 1994; Alle et al., 1998) . Although cyclin E1 locus amplification is rare in breast cancer, the protein product is overexpressed in over 40% of breast carcinomas (Loden et al., 2002) . Cyclin D1 is predominantly overexpressed in ERC tumors, and cyclin E overexpression is confined to ER¡ tumors (Gillett et al., 1994; Alle et al., 1998; Loden et al., 2002) .
The overexpression of several cell cycle regulators has been strongly associated with apoptotic-like behavior, as well as frank apoptosis, in cancer cells, which include c-Myc, E2F-1 and HPV. Apoptosis and its connection to cell cycle-related proteins is of interest therapeutically, as these types therapies could ultimately lead to the cancer cell annihilation via apoptosis.
Recently, a shift has occurred, changing the focus of chemotherapy from exploration of agents that cause cell growth arrest to those that favor apoptosis.
FGFR Tyrosine Kinases
Fibroblast growth factor receptor (FGFR) tyrosine kinases have recently been studied as they relate to intracellular signaling and their effects on pRb, and are of interest to the field of cancer biology. Overexpression of FGFR tyrosine kinases has been found in many human breast carcinomas and has been associated with poor clinical prognosis (Koziczak et al., 2004) .
Fibroblast growth factor receptors (FGFRs) are glycoproteins composed of extracellular immunoglobulin (Ig)-like domains, a hydrophobic transmembrane region and a cytoplasmic moiety that contains a tyrosine kinase domain (Koziczak et al., 2004) . When active, FGFRs stimulate tyrosine phosphorylation, as well as activation of several signaling molecules: Shc, PI3K, Src, PLCg, Crk, SH2 domain containing phosphatase-2 (SHP-2), p38, STAT1/3 and FGFR substrate 2 (FRS2) (Klint and Claesson-Welsh, 1999) . Treatment of tumor cells with the FGFR tyrosine kinase inhibitor leads to a reduction in pRb phosphorylation on serine 795, a site known to be phosphorylated by the cyclin D/cdk4 complex (Koziczak et al., 2004) . FGFR signaling may in fact promote cell proliferation by upregulating cyclin D levels. This idea is supported by the fact that ectopic cyclin D1 expression is able to rescue the FGFR inhibitor-mediated antiproliferative effect (Koziczak et al., 2004) . Using a cyclin D1 reporter gene, Koziczak et al. (2002) found that FGFR inhibitor caused a significant reduction in promoter activity, and was reflected in an overall decrease in cyclin D1 mRNA levels.
A recent study employed p27-deficient mice to investigate the significance of p27 for the metabolism of D-type cyclins in differentiated cells (Bryja et al., 2004) . The absence of p27 resulted in decreased cyclins D2 and/or D3 levels in several organs. The drop in cyclin D levels that was due to the absence of p27 equaled the amount of cyclin D physically associated with p27
animal controls.
The Regulation Pathways of p27 Phosphorylation during Cell Cycling can be viewed at the NCI supported CGAP website:
http://cgap.nci.nih.gov/Pathways/BioCarta/h_p27Pathway).
This indicates the possibility that it is the proportion of p27-associated cyclin D that determines the response to p27 deficiency. Cells in which the D-type cyclin level is dependent on p27 do not upregulate their CDK2 and CDK4 activities upon deactivation of p27. Moreover, these cells have a negligible amount of p27 bound to CDK2 and/or cyclin A/E under non-cancerous conditions (Bryja et al., 2004) . These findings point to the existence of two roles for p27: regulation of the cell cycle through inhibition of CDKs, and participation in the establishment or maintenance of the differentiated status that is achieved in conjunction with D-cyclins (Bryja et al., 2004) .
Ubiquitin
The regulation of protein stability via the ubiquitin-proteasome pathway is critical to the comprehension of the biomolecular basis of cancer development. However, ubiquitin modification of substrates signals many cellular processes (besides proteolysis) that are also important for cancer development. Interestingly, many breast cancer proteins studied by clinical researchers are involved in these specific ubiquitin pathways. These proteins include cyclins, CDK inhibitors and the SCF in cell cycle control, the breast and ovarian cancer suppressor BRCA1-BARD1, ErbB2/HER2/Neu and its ubiquitin ligase c-Cbl, as well as and the estrogen receptor and its target, Efp.
One function of the ubiquitin-proteasome proteolysis pathway is to label proteins for rapid degradation. It consists of four enzymes: a ubiquitin-activating enzyme (E1), a ubiquitinconjugating enzyme (E2), a ubiquitin ligase (E3) and the 26S proteasome (Hershko and Ciechanover, 1998) . E1 binds to and activates ubiquitin in an ATP-dependent manner through a thiolester bond and then transfers ubiquitin to an E2 enzyme. E2 then transfers ubiquitin to a lysine residue in the substrate via a terminal isopeptide bond through E3. E3 is a scaffold protein that bridges in the substrate and the ubiquitin-bound E2. The resultant covalent bonds of the ubiquitin ligations form polyubiquitinated conjugates that are quickly found and digested by the 26S proteasome. Understanding these pathways may provide many critical clues toward the development of novel diagnostic tools and treatments for cancer patients (Ohta and Fukuda, 2004) .
BRCA1-BARD1 Ubiquitin Ligase
The breast and ovarian cancer susceptibility gene BRCA1 is probably the most studied gene in the breast cancer field because of its clinical significance and multiple functions. The BRCA1 gene encodes a 1863-amino-acid protein (Miki et al., 1994 ) that consists of a RING-finger domain in its terminal N-region, a region that includes a nuclear localization signal and a domain that binds to many cellular proteins, and tandem BRCT domains in its C-terminal region. BRCA1
is associated with a diverse range of biological processes, such as DNA repair, cell cycle control, transcriptional regulation, apoptosis and centrosome duplication. The only known biochemical function of BRCA1 is E3 ubiquitin ligase activity (Table 1 ). The N-terminal RING finger domain of BRCA1 interacts with another conformationally similar RING finger protein, BARD1 (Wu et al., 1996; Brzovic et al., 2001) , that also contains an N-terminal RING domain and C-terminal BRCT domains (Wu et al., 1996) . BRCA1 attains high ubiquitin ligase activity when bound to BARD1 as a heterodimer (Hashizume et al., 2001) . Importantly missense mutations in the RINGfinger domain of BRCA1 found in familial breast cancer all eradicate the ubiquitin ligase activity of BRCA1-BARD1 (Hashizume et al., 2001; Ruffner et al., 2001; Brzovic et al., 2003) . This fact suggests a strong link between BRCA1 ligase activity and its function as a tumor suppressor. The analysis of ubiquitin ligase activity of RING-domain mutations is important not only for the investigation of the biological function of BRCA1, but also to be able to predict a specific patient's propensity for cancer, which may influence the need for prophylactic surgeries.
Ubiquitin E3 ligases and their targets related to breast cancer
Besides enhancing BRCA1's ubiquitin ligase activity, BARD1 is also critical for BRCA1 stability in vivo (Hashizume et al., 2001; Joukov et al., 2001; Xia et al., 2003) . Loss of BARD1 leads to a phenotype similar to that of the loss of BRCA1, that is, early embryonic lethality/ chromosomal instability (McCarthy et al., 2003) . Moreover, germline mutations of BARD1 are found in breast and ovarian cancer patients (Thai et al., 1998) . Although ubiquitin ligase activity may be significant for the role of the BRCA1 gene as a tumor suppressor, the way the activity contributes to BRCA1's biological function remains unknown. Two issues exist that are critical to the elucidation of the role of the BRCA1-BARD1 ubiquitin ligase: the type of polyubiquitin chain built by BRCA1-BARD1 (and its consequences), and the specific identity of its substrates.
In the past decade researchers have identified important functional roles for the D-and Etype cyclins in the evolution of human breast cancers. These genes are among the most commonly overexpressed genes in breast cancer, being overexpressed in the early phases of disease and having proven oncogenic effects on mammary epithelial cells both in vitro as well as in vivo.
Their established role in CDK activation and Rb pathway regulation has directed scientific attention toward aberrant cell cycling as the basis of oncogenic potential. More recent data on the role of different G1 cyclins in the areas of differentiation, chromosome stability and transcriptional regulation indicate that their role in breast cancer is much more complex than initially predicted.
Further investigations may yield a more complete understanding of the role of these cyclins regarding the biomolecular basis and pathophysiology of breast cancer, with significant potential benefits clinically, through the identification of novel markers of prognosis and therapeutic responsiveness and potential new targets for innovative clinical intervention.
Signal Transduction Modulators as Novel Anticancer Drugs
Recently, there has been an increasing number of reports that cancer frequently involves pathogenic mechanisms which give rise to numerous alterations in signal transduction pathways.
Therefore, novel therapeutic agents that target specific signal transduction molecules or signaling (Salomon et al., 1995; Gullick et al., 1991) .
Overexpression of EGFR is associated with increased invasiveness, resistance to treatment and poor outcomes in several tumor types (Neal et al., 1985; Ke et al., 1998) . Iressa is found to be effective in the treatment of: Non-small cell lung (NSCLC), colorectal, head and neck, bladder, brain, pancreas, breast, ovarian, prostate and gastric cancer types that were previously unresponsive to other chemotherapy (Salomon et al., 1995; Gullick et al., 1991) . ZD 1839 ( subjects, 9 achieved a partial response and 9 had a minor response or stability. A randomized, placebo-controlled phase III study was performed to determine efficacy and safety of adding trastuzumab to chemotherapy in breast carcinoma. 28% of patients treated with both were disease progression-free at 12 months, compared with 9% of the patients treated only with chemotherapy.
The treatment is indicated as a single agent for patients that have failed earlier therapy, and it is used also as first-line treatment for metastatic disease when used in combination with paclitaxel.
Trustuzumab has been approved by the FDA for use in women with metastatic breast cancer with HER2-positive tumors.
Cetuximab. An antibody-based approach to affecting tyrosine kinase signaling is by cetuximab, a humanized monoclonal antibody against the EGFR. MAb225, a murine monoclonal antibody that specifically binds to EGFR, specifically competes with signal transduction initiated by TGF- (Gill et al., 1984) . Cetuximab (C225) is the human-mouse chimeric version of Mab225, which specifically binds to the EGFR with high affinity, preventing the ligand from interacting with the receptor. Preclinical studies show that cetuximab results in cell-cycle arrest as well as apoptosis in different contexts (Huang et al., 1999; Peng et al., 1996) . A synergistic effect of cetuximab with cytotoxic chemotherapy has been seen with cisplatin, doxorubicin (Baselga et al., Bryostatin. The bryostatins represent a large family of secondary metabolites produced in extremely small amounts by the marine invertebrate, Bugula neritina of the phylum Ectoprocta (Pettit et al., 1991) . The various bryostatins are distinguished by varying side chains off the macrocyclic lactone ring structure. Despite this close structural relationship, these nontumorpromoting PKC activators have different biologic activities and spectrum of toxicity (Kraft et al., 1996; Jones et al., 1990) . Bryostatin 1 (Bryo 1) is the prototype of this 17-member family and the most extensively studied in humans. Initial isolation of Bryo 1 was based on its antineoplastic activity against the murine P388 lymphocytic leukemia. Bryo 1 is a potent and rapid activator of PKC; however, unlike other PKC activators, including phorbol myristate acetate (PMA), Bryo 1 lacks tumor-promoting capabilities. The first two published phase I trials evaluated Bryo 1 administered as a 1 h intravenous infusion (Prendiville et al., 1993; Philip et al., 1993) . The DLT was myalgia, occurring approximately 48 h after treatment and lasting up to several weeks at the highest dose levels (65 g/m 2 /dose). The MTD was 50 g/m 2 , and the recommended dose for phase II trials was 35 to 50 g/m 2 every two weeks. Partial responses were observed in two patients with malignant melanoma, which lasted 6 months and 10 months. Plasma levels of tumor necrosis factor-alpha (TNF-) and interleukin-6 (IL-6) increased 2 h and 24 h after treatment, respectively, and were dose related.
UCN-01 (7-OH Staurosporine): Staurosporine, a natural product isolated from
Streptomyces staurosporeus, is a relatively broad, nonspecific protein kinase antagonist, originally isolated in an effort to define inhibitors of protein kinase C (PKC). 7-OH staurosporine (UCN-01) was defined as a more selective, but not specific, PKC antagonist. Two prominent effects of UCN- UCN-01 abrogates the DNA damage-induced checkpoints to cell-cycle progression in G2 (Bunch et al., 1996; Wang et al., 1996) and in S phase (Shao et al., 1997) . It is noteworthy that these effects were apparent at drug concentrations that appeared to have little direct effect on cell proliferation or that caused enhanced cytotoxicity by clonogenic or proliferation assays. In addition, they provided a mechanistic framework for prior observations that DNA-damaging agents such as mitomycin (Akinaga et al., 1993) 
Farnesyl Transferase Inhibitors
Ras genes are mutated in 30% of all human cancers with K-Ras being the most common. bond formation between a farnesyl group (C15) and a cysteine residue at the ras carboxy terminus.
A "GTT shunt pathway" maintains K-Ras in an active prenylated, membrane-bound form and explains in part the requirements for higher farnesyl transferase inhibitor (FTI) dose or cotreatment with a GTT inhibitor for significant growth inhibition in K-Ras models (Pendergast et al., 2000) .
Several classes of FTIs have been developed in an initial effort to define inhibitors of Ras function
and, in general, compete with the enzyme substrates, the CAAX tetrapeptide, and farnesyl pyrophosphate (FFP). The CAAX competitors are generally peptidomimetic agents that mimic the carboxy terminal portion of the Ras protein.
SCH66336 is a novel oral agent derived from a class of nonpeptide, nonthiol-containing, CAAX mimetic FTIs (Bishop et al., 1995) . The drug inhibits in vitro FT activity with an IC 50 of 1.9 nM for H-ras, 2.8 nM for N-ras, and 5.2 nM for K-ras. Inhibition of cells with activated ras and anchorage-independent growth was noted with IC 50 75 nM in H-ras versus 400 nM with K-rasdriven cells (Liu et al., 1999) . The observed growth inhibition of tumor cells in soft agar and in xenografts was independent of ras mutational status because even wild-type ras cells were sensitive (Liu et al., 1998) . The phase I experience with SCH66336 involved 20 patients using a twice a day schedule over 7 days every 21 days. Eight patients had stable disease, and treatment for up to 10 cycles was possible in a few patients. Antitumor activity was reported in one patient with advanced NSCLC who had a greater than 50% reduction in an adrenal metastasis and received treatment for 14 months (Adjei et al., 2000) . 
Evaluation of Results and Related Developments
The Another important aspect that must be considered is the need for accurate means of diagnosing the dependence of a tumor on a particular signaling pathway, or target, for novel therapeutic strategies.
All of problems and drawbacks considered here call for renewed efforts to define improved assays of target effects in the preclinical phase of a drug' s development that can also be translated to the clinical arena. Microarray, proteomic and interactomic, approaches offer the promise of providing such means (Mohr, S. et al., 2002) but these must also be integrated into the clinical trials process.
The vast amounts of data becoming available from such high throughput measurements with microarrays on human tumors and tissues also require the employment of powerful computers, effective algorithms for data computational analysis, as well as major advances in our understanding of the complex systems dynamics of cancer cells, malignant tumors and tumorimmune interactions in human subjects. Furthermore, higher sensitivity, faster and less expensive diagnostic means must be developed and tested in the clinic to establish their applicability to different types of cancer, and also for the early detection of cancer. Molecular profiling and selective molecular imaging of cancer in human subjects are two such closely related diagnostic means that would make possible individualized cancer therapy, as well as provide the ability to proceed with economically feasible screening of human populations that are considered to be at risk for specific types of cancer by utilizing relatively inexpensive and non-invasive means for early detection of cancer. NIR and fluorescence microspectroscopy based techniques are two such very promising means for the early detection of cancer, as well as for the effective monitoring of the cancer therapy effects in patients, thus also providing the accurate means for diagnosing the dependence of a tumor on a particular signaling pathway, or target, for novel therapeutic strategies.
